SCHEMBL4353450

SCHEMBL4353450

NCc1ncccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4537543 0.98 DPP4 (0.49)
Hydrochloric Acid SCHEMBL30818111 0.81 TAAR1 (0.47)
Hydrochloric Acid SCHEMBL29168289 0.81 TAAR1 (0.47)
SCHEMBL4347152 0.79
SCHEMBL10796757 0.78 HRH1 (0.49)
SCHEMBL20897489 0.77
SCHEMBL30642875 0.77
SCHEMBL2894722 0.77
SCHEMBL1161332 0.77
SCHEMBL4455152 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9176121-A None JP disclosed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 US disclosed
EP-4615439-A2 SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS Humanwell Pharmaceutical US, Inc. (US) 2025-09-17 EP disclosed
US-20250170141-A1 MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT INCYTE CORPORATION 2025-05-29 US disclosed
EP-4326717-B1 MODIFIED FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2025-04-16 EP disclosed
WO-2025076455-A1 MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT Escient Pharmaceuticals Inc. (US) 2025-04-10 WO disclosed
US-20240239780-A1 MODIFIED FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2024-07-18 US disclosed
US-20240174693-A1 SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) 2024-05-30 US disclosed
WO-2024102754-A2 SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS HUMANWELL PHARMACUETICAL US, INC. (US) 2024-05-16 WO disclosed
CN-101370765-A Method for selectively producing primary amine SUMITOMO CHEMICAL CO (JP) 2009-02-18 CN disclosed
US-7482357-B2 17-acetamido-4-azasteroid derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-01-27 US disclosed
US-7482357-B2 17-acetamido-4-azasteroid derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-01-27 US disclosed
EP-1961733-A1 METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-08-27 EP disclosed
US-20030158218-A1 Thrombin inhibitors NANTERMET PHILIPPE G (US) 2003-08-21 US disclosed
JP-H09176121-A PRODUCTION OF CHLORO-(AMINOMETHYL)PYRIDINES KOEI CHEM CO LTD 1997-07-08 JP disclosed
US-4794121-A ANTISPASMODIC, BRONCHODILATOR, ANTICONVULSANT, ANALGESIC, HYPOTENSIVE, OR BRADYCARDIAL AGENT; ADRENERGIC STIMULANT PANMEDICA (FR) 1988-12-27 US disclosed
US-4112100-A INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-4069224-A N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS THE UPJOHN COMPANY (US) 1978-01-17 US disclosed
US-4008326-A INCREASING PRODUCTION OF PROSTAGLANDINS THE UPJOHN COMPANY (US) 1977-02-15 US disclosed